PTC Therapeutics, Inc. (PTCT)
Largest Insider Buys in Sector
PTCT Stock Price History Chart
PTCT Stock Performance
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic …
Insider Activity of PTC Therapeutics, Inc.
Over the last 12 months, insiders at PTC Therapeutics, Inc. have bought $198,736 and sold $2.3M worth of PTC Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at PTC Therapeutics, Inc. have bought $424,214 and sold $22.4M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Gravier Pierre (CHIEF FINANCIAL OFFICER) — $198,736.
The last purchase of 7,700 shares for transaction amount of $198,736 was made by Gravier Pierre (CHIEF FINANCIAL OFFICER) on 2023‑12‑12.
List of Insider Buy and Sell Transactions, PTC Therapeutics, Inc.
| 2024-07-16 | Sale | CHIEF FINANCIAL OFFICER | 2,269 0.0029% | $34.02 | $77,200 | +3.37% | ||
| 2024-05-22 | Sale | director | 20,000 0.0258% | $38.24 | $764,800 | -7.33% | ||
| 2024-05-07 | Sale | EVP & CHIEF MEDICAL OFFICER | 175 0.0002% | $32.82 | $5,744 | +11.69% | ||
| 2024-04-19 | Sale | CHIEF EXECUTIVE OFFICER | 3,361 0.0043% | $24.89 | $83,669 | +38.90% | ||
| 2024-04-17 | Sale | CHIEF EXECUTIVE OFFICER | 1,307 0.0017% | $25.14 | $32,851 | +39.44% | ||
| 2024-04-17 | Sale | CHIEF EXECUTIVE OFFICER | 787 0.001% | $25.14 | $19,781 | +39.44% | ||
| 2024-04-02 | Sale | EVP & CHIEF MEDICAL OFFICER | 526 0.0007% | $28.37 | $14,923 | +22.92% | ||
| 2024-01-30 | Sale | EXEC. VP AND CLO | 794 0.0011% | $27.25 | $21,637 | +23.48% | ||
| 2024-01-30 | Sale | CHIEF BUSINESS OFFICER | 366 0.0005% | $27.25 | $9,974 | +23.48% | ||
| 2024-01-30 | Sale | SVP, CHIEF ACCOUNTING OFFICER | 318 0.0004% | $27.25 | $8,666 | +23.48% | ||
| 2024-01-30 | Sale | CHIEF TECHNICAL OPS OFFICER | 646 0.0009% | $27.25 | $17,604 | +23.48% | ||
| 2024-01-22 | Sale | director | 10,000 0.0133% | $27.38 | $273,804 | +19.19% | ||
| 2024-01-09 | Sale | CHIEF EXECUTIVE OFFICER | 5,443 0.0073% | $29.01 | $157,928 | +12.70% | ||
| 2024-01-09 | Sale | EXEC. VP AND CLO | 1,938 0.0026% | $29.01 | $56,231 | +12.70% | ||
| 2024-01-09 | Sale | CHIEF BUSINESS OFFICER | 2,065 0.0028% | $29.01 | $59,916 | +12.70% | ||
| 2024-01-09 | Sale | CHIEF MEDICAL OFFICER | 1,225 0.0016% | $29.01 | $35,543 | +12.70% | ||
| 2024-01-09 | Sale | SVP, FINANCE & CAO | 1,653 0.0022% | $29.01 | $47,961 | +12.70% | ||
| 2024-01-09 | Sale | CHIEF TECHNICAL OPS OFFICER | 1,621 0.0022% | $29.01 | $47,033 | +12.70% | ||
| 2024-01-08 | Sale | CHIEF EXECUTIVE OFFICER | 2,237 0.0029% | $28.64 | $64,068 | +8.48% | ||
| 2024-01-08 | Sale | director | 1,500 0.0019% | $27.81 | $41,715 | +8.48% |
Insider Historical Profitability
| SCHMERTZLER MICHAEL | director | 115266 0.1495% | $43.28 | 5 | 2 | +30.17% |
| Gravier Pierre | CHIEF FINANCIAL OFFICER | 53531 0.0694% | $43.28 | 1 | 1 | |
| HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 2441504 3.1656% | $43.28 | 1 | 1 | +8.52% |
| Koppel Adam | director | 2333333 3.0254% | $43.28 | 1 | 0 | +8.52% |
| Vulcan Ventures Inc. | director | 803067 1.0413% | $43.28 | 1 | 0 | +8.52% |
Institutional Investor Ownership
| The Vanguard Group | $272.54M | 12.22 | 9.37M | +6.46% | +$16.53M | 0.01 | |
| Wellington Management Company | $258.95M | 11.61 | 8.9M | -9.32% | -$26.62M | 0.04 | |
| BlackRock | $220.07M | 9.86 | 7.57M | -0.9% | -$2.01M | 0.01 | |
| RTW Investments, LP | $215.96M | 9.68 | 7.42M | 0% | +$0 | 3.24 | |
| Armistice Capital Llc | $196.76M | 8.82 | 6.76M | -1.46% | -$2.91M | 0.63 |